Product nameAnti-Cytosolic Phospholipase A2 (phospho S505) antibody [EPR18552]
See all Cytosolic Phospholipase A2 primary antibodies
DescriptionRabbit monoclonal [EPR18552] to Cytosolic Phospholipase A2 (phospho S505)
Tested applicationsSuitable for: Dot blot, IP, WBmore details
Species reactivityReacts with: Mouse
within Human Cytosolic Phospholipase A2 aa 450-550 (phospho S505). The exact sequence is proprietary.
Database link: P47712
- NIH/3T3 treated with 20 ng/ml TNF-alpha for 10 minutes whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
Our Abpromise guarantee covers the use of ab191605 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000. Detects a band of approximately 100 kDa (predicted molecular weight: 85 kDa).|
FunctionSelectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Tissue specificityExpressed in various tissues such as macrophages, platelets, neutrophils, fibroblasts and lung endothelium.
Sequence similaritiesContains 1 C2 domain.
Contains 1 PLA2c domain.
DomainThe N-terminal C2 domain associates with lipid membranes upon calcium binding. It modulates enzyme activity by presenting the active site to its substrate in response to elevations of cytosolic Ca(2+).
modificationsActivated by phosphorylation at both Ser-505 and Ser-727.
Cellular localizationCytoplasm. Cytoplasmic vesicle. Translocates to membrane vesicles in a calcium-dependent fashion.
- Information by UniProt
- Calcium dependent phospholipid binding protein antibody
- CPLA 2 antibody
- cPLA2 alpha antibody
All lanes : Anti-Cytosolic Phospholipase A2 (phospho S505) antibody [EPR18552] (ab191605) at 1/2000 dilution
Lane 1 : Untreated NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate
Lane 2 : NIH/3T3 (Mouse embryonic fibroblast cell line) treated with 20 ng/ml TNF-alpha for 10 minutes whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 85 kDa
Observed band size: 100 kDa why is the actual band size different from the predicted?
Exposure time: 10 seconds
Blocking/Dilution buffer: 5% NFDM/TBST.
ab191605 at 1/50 dilution immunoprecipitating Cytosolic Phospholipase A2 (phospho S505) in NIH/3T3 (mouse embryo) whole cell lysate.
Lane 1 (input): NIH/3T3 cells treated with 20ng/ml TNF-a for 60min whole cell lysate 10μg
Lane 2 (+): ab191605 + NIH/3T3 cells treated with 20ng/ml TNF-a for 60min whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab191605 in NIH/3T3 cells treated with 20ng/ml TNF-a for 60min whole cell lysate
For western blotting, ab191605 1/1000 dilution and VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Blocking and Diluting buffer and concentration: 5% NFDM/TBST.
Dot blot analysis of Cytosolic Phospholipase A2 (phospho S505) phospho peptide (Lane 1) and Phospholipase A2 Non-phospho peptide (Lane 2) labeled using ab191605 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) secondary antibody at 1/100000 dilution.
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
ab191605 has not yet been referenced specifically in any publications.